Navigation Links
Electrical pulse treatment pokes holes in hard-to-treat tumors
Date:4/14/2013

NEW ORLEANS (April 14, 2013)A new, minimally invasive treatment that tears microscopic holes in tumors without harming healthy tissue is a promising treatment for challenging cancers, suggests a preliminary study being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans.

"Irreversible electroporation (or IRE) is a new way to attack cancer, using microsecond electrical pulses to kill cancer at the cellular level without damaging healthy tissue nearby. It may be especially beneficial in treating liver, lung, pancreatic and other cancers that are close to blood vessels, nerves and other sensitive structures," said Constantinos T. Sofocleous, M.D., Ph.D., FSIR, lead author and interventional radiologist at Memorial Sloan-Kettering Cancer Center in New York, N.Y. "IRE appears to be especially beneficial in people with cancer that has spread beyond the primary tumor who do not have good treatment options," he added. "IRE uses strong electric fields to create tiny holes in the cell membrane, killing the cancer by disrupting the balance between the molecules inside and outside the cellwithout resulting in other cell damage. This makes IRE potentially ideal for treating tumors close to sensitive structures," said Sofocleous.

Whereas other treatmentssuch as surgery, or heating and freezing (also known as thermal ablation)can damage healthy tissue near the tumor, IRE precisely perforates the cancer cells, posing fewer risks to major blood vessels, nerves, bile ducts and other vital structures, he said.

IRE has been shown to be safe in the treatment of cancers that have metastasized, or spread, to the liver, lung, bladder and the pelvic region. In this study, 25 participants with a total of 40 metastases to the liver from lung, pancreas, thyroid gland, prostate, uterus and uterine lining, ovaries and rectum primaries, were treated with IRE. The average size of the tumors was about two centimeters. IRE was used due to the location of the lesions, near critical structures that would be affected by thermal ablation. Researchers completed all 30 treatment sessions with no major complications, showing IRE to be safe enough for further investigation and expansion of its use to large clinical trials.

IRE is on the frontier of interventional radiology treatments that are nonsurgical and involve minimal risk and downtime for cancer patients. Interventional radiologist treatments involve making incisions the size of a pencil tip and use medical imaging to guide tiny instruments to the targeted tumors.

"Using the least-invasive treatments available, interventional radiologists are able to destroy entire tumors with a needle and image guidance," said Sofocleous. "We often treat patients who have no other conventional treatment options or have such poor health that even minimally invasive surgery is too dangerous. Researchers are working to increase the effectiveness of IRE and eventually will test it against other treatments for these tumors, including radiofrequency ablation, microwave ablation and cryoablation," he noted.


'/>"/>

Contact: Ellen Acconcia
eacconcia@sirweb.org
703-460-5582
Society of Interventional Radiology
Source:Eurekalert

Related medicine news :

1. Electrical Stimulation Could Zap the Need for Physical Therapy Following Knee Replacement
2. Functional electrical stimulation cycling promotes recovery in chronic spinal cord injury
3. Electrical Brain Stimulation Plus Drug Fights Depression: Study
4. After 100 years, understanding the electrical role of dendritic spines
5. New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
6. Electrical characteristics of printed products determined in a snap
7. Electrical Brain Stimulation Curbs Epileptic Seizures in Rats
8. Unprecedented accuracy in locating brain electrical activity with new device
9. Electrical brain stimulation can alleviate swallowing disorders after stroke
10. Hopkins Medical Products Introduces The Wave™ Pulse Oximeter
11. Intense terahertz pulses cause DNA damage but also induce DNA repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Reflections Recovery Center, a men-only drug ... Joint Commission for chemical dependency and behavioral health services. , The Joint Commission ... that meet the commission’s rigorous standards. Accreditation by The Joint Commission is the ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Doctors on ... to their qualified network of medical professionals working on a personal injury lien basis. ... Spine Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients ...
(Date:9/20/2017)... Ohio (PRWEB) , ... September 20, 2017 , ... ... to customer service and innovation, the company recently unveiled a redesigned website. The ... further enrich the work of building owners, architects, contractors and other industry users ...
(Date:9/20/2017)... ... , ... Five consumer packaged goods (CPG) products were selected by the SupplySide ... Nopavera Plus was named to the short list in the Specialty Supplements category. ... presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive God’s ... emotionally pens his aspirations and goals to better one’s life through God. “The Trials ... while searching in all the wrong places, found a love for writing. Green feels ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: